Phaseline

Targets › CXCR1

CXCR1 (C-X-C chemokine receptor type 1): drug programs, companies and trials

4 programs from 4 companies in 18 trials: 11 Phase 1, 6 Phase 2, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Jan 2027.

Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. (UniProt, P25024)

Open in Phaseline: the race on CXCR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Memorial Sloan Kettering Cancer CenterBIO 300
Interleukin-8 receptors, CXCR1/CXCR2 inhibitor
CXCR2, CXCR1Phase 3Multiple Myeloma; NSCLC; Diarrhea; Cutaneous Squamous Cell Carcinoma …Jan 2027
Syntrix BiosystemsSX-682
Interleukin-8 receptors, CXCR1/CXCR2 inhibitor
CXCR2, CXCR1Phase 2Metastatic Castration-resistant Prostate Cancer; Melanoma Stage III; Myelodysplastic Syndromes; Metastatic Lung Non-Small Cell Carcinoma …Jun 2027
Icahn School of Medicine at Mount Sinaireparixin
Interleukin-8 receptor A modulator; Interleukin-8 receptor B modulator
CXCR1, CXCR2Phase 2Myelofibrosis (PMF)Dec 2027
NYU Langone HealthLadarixin
Interleukin-8 receptor A modulator; Interleukin-8 receptor B modulator
CXCR1, CXCR2Phase 1Advanced Non-small Cell Lung Cancer With KRAS G12C MutationAug 2027

Conditions

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation (1) Myelofibrosis (PMF) (1) Metastatic Castration-resistant Prostate Cancer (1) Melanoma Stage III (1) Myelodysplastic Syndromes (1) Metastatic Lung Non-Small Cell Carcinoma (1) Pancreatic Cancer (1) Advanced Lung Non-Small Cell Carcinoma (1) Pancreatic Ductal Adenocarcinoma (1) Recurrent Multiple Myeloma (1) Metastatic Colorectal Cancer (1) Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (1)

Modalities

small molecule (4)

Companies

NYU Langone Health (1) Icahn School of Medicine at Mount Sinai (1) Syntrix Biosystems (1) Memorial Sloan Kettering Cancer Center (1)

Related targets

CXCR2 (4)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.